Page 615 - Cardiac Nursing

3 P
3 P
1:4
M
p
94.
M
55
55
p
5-5
1:4
0
5-5
3
3
0/0
3
q
xd
xd
ara
t
t
ara
0/0
q
q
009
009
p
0
91
e 5
94.
LWBK340-c24_
LWB
LWB K34 0-c 24_ pp555-594.qxd 30/06/2009 01:43 PM Page 591 Aptara
K34
p
24_
0-c
Pa
p
g
g
Pa
g
6/2
6/2
91
e 5
A
A
C HAPTER 24 / Heart Failure and Cardiogenic Shock 591
73. Cohn, J. N., & Tognoni, G. (2001). A randomized trial of the an- 94. Leibundgut, G., Pfisterer, M., & Brunner-La Rocca, H. P. (2007). Drug
giotensin-receptor blocker valsartan in chronic heart failure. New Eng- treatment of chronic heart failure in the elderly. Drugs and Aging, 24(12),
land Journal of Medicine, 345(23), 1667–1675. 991–1006.
74. McMurray, J. J., Ostergren, J., Swedberg, K., et al. (2003). Effects of can- 95. Rutten, J. H. W., Steyerberg, E. W., Boomsma, F., et al. (2008). N-
desartan in patients with chronic heart failure and reduced left-ventricular terminal pro-brain natriuretic peptide testing in the emergency depart-
systolic function taking angiotensin-converting-enzyme inhibitors: The ment: Beneficial effects on hospitalization, costs, and outcome. American
CHARM-added trial. Lancet, 362(9386), 767–771. Heart Journal, 156(1), 71–77.
6
6
75. Granger, C. B., McMurray, J. J., Yusuf, S., et al. (2003). Effects of can- 96. Owan, T. E., Chen, H. H., Frantz, R. P., et al. (2008). The effects of ne-
desartan in patients with chronic heart failure and reduced left-ventricular siritide on renal function and diuretic responsiveness in acutely decom-
systolic function intolerant to angiotensin-converting-enzyme inhibitors: pensated heart failure patients with renal dysfunction. Journal of Cardiac
The CHARM-alternative trial. Lancet, 362(9386), 772–776. Failure, 14(4), 267–275.
76. Struthers, A. D. (2004). Aldosterone blockade in cardiovascular disease. 97. Elkayam, U., Bitar, F., Akhter, M. W., et al. (2004). Intravenous nitroglyc-
Heart, 90(10), 1229–1234. erin in the treatment of decompensated heart failure: Potential benefits and
77. Chai, W., Garrelds, I. M., de Vries, R., et al. (2005). Nongenomic effects limitations. Journal of Cardiovascular Pharmacology and Therapeutics, 9(4),
of aldosterone in the human heart: Interaction with angiotensin II. Hy- 227–241.
pertension, 46(4), 701–706. 98. Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005).
6
6
78. Khan, N. U., & Movahed, A. (2004). The role of aldosterone and aldos- Risk of worsening renal function with nesiritide in patients with acutely
terone-receptor antagonists in heart failure. Reviews in Cardiovascular decompensated heart failure. Circulation, 111(12), 1487–1491.
Medicine, 5(2), 71–81. 99. Echt, D. S., Liebson, P. R., Mitchell, L. B., et al. (1991). Mortality and
79. Pitt, B., Zannad, F., Remme, W. J., et al. (1999). The effect of spirono- morbidity in patients receiving encainide, flecainide, or placebo. The
lactone on morbidity and mortality in patients with severe heart failure. Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine,
Randomized Aldactone Evaluation Study Investigators. New England 324(12), 781–788.
Journal of Medicine, 341(10), 709–717. 100. Chapa, D. W., Lee, H. J., Kao, C. W., et al. (2008). Reducing mor-
80. Azuma, J., & Nonen, S. (2008). Chronic heart failure: Beta-blockers and tality with device therapy in heart failure patients without ventricular
7
7
pharmacogenetics. European Journal of Clinical Pharmacology. arrhythmias. American Journal of Critical Care, 17(5), 443–452; quiz
81. Fonarow, G. C. (2008). A review of evidence-based beta-blockers in spe- 453.
cial populations with heart failure. Reviews in Cardiovascular Medicine, 101. Russo, A. M., Poole, J. E., Mark, D. B., et al. (2008). Primary prevention
9(2), 84–95. with defibrillator therapy in women: Results from the Sudden Cardiac
82. Bristow, M. R., Krause-Steinrauf, H., Nuzzo, R., et al. (2004). Effect of Death in Heart Failure Trial. Journal of Cardiovascular Electrophysiology,
baseline or changes in adrenergic activity on clinical outcomes in the 19(7), 720–724.
beta-blocker evaluation of survival trial. Circulation, 110(11), 102. Bardy, G. H., Lee, K. L., Mark, D. B., et al. (2005). Amiodarone or an
1437–1442. implantable cardioverter-defibrillator for congestive heart failure. New
83. Gilbert, E. M., O’Connell, J. B., & Bristow, M. R. (1991). Therapy of England Journal of Medicine, 352(3), 225–237.
idiopathic dilated cardiomyopathy with chronic beta-adrenergic block- 103. Suskin, N., McKelvie, R. S., Burns, R. J., et al. (2000). Glucose and in-
6
6
ade. Heart and Vessels Supplement, 6, 29–39. sulin abnormalities relate to functional capacity in patients with conges-
84. Tate, C. W., III, Robertson, A. D., Zolty, R., et al. (2007). Quality of tive heart failure. European Heart Journal, 21(16), 1368–1375.
life and prognosis in heart failure: Results of the Beta-Blocker Evalua- 104. Ingelsson, E., Sundstrom, J., Arnlov, J., et al. (2005). Insulin resistance
tion of Survival Trial (BEST). Journal of Cardiac Failure, 13(9), and risk of congestive heart failure. JAMA, 294(3), 334–341.
732–737. 105. Stratton, I. M., Adler, A. I., Neil, H. A., et al. (2000). Association of gly-
85. Varadarajan, P., Joshi, N., Appel, D., et al. (2008). Effect of beta-blocker caemia with macrovascular and microvascular complications of type 2 di-
therapy on survival in patients with severe mitral regurgitation and nor- abetes (UKPDS 35): Prospective observational study. BMJ, 321
mal left ventricular ejection fraction. American Journal of Cardiology, (7258), 405–412.
102(5), 611–615. 106. Kostis, J. B., & Sanders, M. (2005). The association of heart failure with
86. Hjalmarson, A., Goldstein, S., Fagerberg, B., et al. (2000). Effects of insulin resistance and the development of type 2 diabetes. American Jour-
controlled-release metoprolol on total mortality, hospitalizations, and nal of Hypertension, 18(5, Pt. 1), 731–737.
well-being in patients with heart failure: The Metoprolol CR/XL Ran- 107.Dutka, D. P., Pitt, M., Pagano, D., et al. (2006). Myocardial glucose
domized Intervention Trial in Congestive Heart Failure (MERIT-HF). transport and utilization in patients with type 2 diabetes mellitus, left
JAMA, 283(10), 1295–1302. ventricular dysfunction, and coronary artery disease. Journal of the Amer-
87. O’Connor, C. M., Gattis, W. A., Zannad, F., et al. (1999). Beta-blocker ican College of Cardiology, 48(11), 2225–2231.
therapy in advanced heart failure: Clinical characteristics and long-term 108. Annual U.S. Deaths Attributable to Smoking 1997–2001. (2005). Center
outcomes. European Journal of Heart Failure, 1(1), 81–88. for Disease Control and Prevention.
88. Houghton, T., Freemantle, N., & Cleland, J. G. (2000). Are beta-blockers 109. Bibbins-Domingo, K., Lin, F., Vittinghoff, E., et al. (2004). Predictors of
effective in patients who develop heart failure soon after myocardial in- heart failure among women with coronary disease. Circulation, 110(11),
farction? A meta-regression analysis of randomised trials. European Journal 1424–1430.
of Heart Failure, 2(3), 333–340. 110. Suskin, N., Sheth, T., Negassa, A., et al. (2001). Relationship of current
89. Tatli, E., & Kurum, T. (2005). A controlled study of the effects of and past smoking to mortality and morbidity in patients with left ven-
7
7
carvedilol on clinical events, left ventricular function and proinflamma- tricular dysfunction. Journal of the American College of Cardiology, 37(6),
tory cytokines levels in patients with dilated cardiomyopathy. Canadian 1677–1682.
Journal of Cardiology, 21(4), 344–348. 111. Goldstein, M. G., Niaura, R., Willey-Lessne, C., et al. (1997). Physicians
90. Cohn, J. N. (2001). Optimal diuretic therapy for heart failure. American counseling smokers. A population-based survey of patients’ perceptions of
Journal of Medicine, 111(7), 577. health care provider-delivered smoking cessation interventions. Archives of
7
91. Harjola, V. P., Oikarinen, L., Toivonen, L., et al. (2008). The hemody- Internal Medicine, 157(12), 1313–1319.
7
namic and pharmacokinetic interactions between chronic use of oral lev- 112. Nohria, A., Chen, Y. T., Morton, D. J., et al. (1999). Quality of care for
osimendan and digoxin in patients with NYHA Classes II–III heart fail- patients hospitalized with heart failure at academic medical centers.
7
7
ure. International Journal of Clinical Pharmacology and Therapeutics, American Heart Journal, 137(6), 1028–1034.
6
46(8), 389–399. 113. Rice, V. H., & Stead, L. F. (2008). Cochrane Database System Review, 1:
6
92. Dulin, B. R., & Krum, H. (2006). Drug therapy of chronic heart failure CD00118.
in the elderly: The current state of clinical-trial evidence. Current Opin- 114. Fonarow, G. C., Yancy, C. W., Heywood, J. T., et al. (2005). Adherence
ion in Cardiology, 21(4), 393–399. to heart failure quality-of-care indicators in US hospitals: Analysis of the
93. Ahmed, A., Pitt, B., Rahimtoola, S. H., et al. (2008). Effects of digoxin ADHERE registry. Archives of Internal Medicine, 165(13), 1469–1477.
at low serum concentrations on mortality and hospitalization in heart 115. Androne, A. S., Katz, S. D., Lund, L., et al. (2003). Hemodilution is
7
7
failure: A propensity-matched study of the DIG trial. International Jour- common in patients with advanced heart failure. Circulation, 107(2),
nal of Cardiology, 123(2), 138–146. 226–229.